Effect of Nebivolol on Outcome in Elderly Patients with Heart Failure and Atrial Fibrillation: Insights from SENIORS
Key result
Nebivolol failed to reduce all-cause mortality or cardiovascular hospitalizations vs placebo in elderly heart failure patients with atrial fibrillation (HR 0.92; 95% CI 0.73-1.17; P=0.46).
Authors
Discussion
Loading...
Member takes
Implication
Nebivolol should not be used to reduce mortality or hospitalizations in elderly HF with AF; confirms neutral beta-blocker effects in this subgroup.
Study Design
Type
RCT (n=2,128)
PICO
P
Population
2,128 heart failure patients >70 years of age, including 738 with atrial fibrillation, followed for 21 months.
I
Intervention / Comparator
Nebivolol vs Placebo
O
Primary Outcome
All-cause mortality or cardiovascular hospitalizations — HR 0.92 (0.73-1.17), p=0.46
Main Result
Hazard Ratio: 0.92 (95% CI 0.73–1.17)
Absolute Event Rate: 37.1% vs 39.8%
p-value: p=0.46
Cite This Study
Mulder et al. (2012) conducted an RCT in Heart failure and atrial fibrillation (n=2,128). Nebivolol vs. Placebo was evaluated on All-cause mortality or cardiovascular hospitalizations (HR 0.92, 95% CI 0.73-1.17, p=0.46). Nebivolol failed to reduce all-cause mortality or cardiovascular hospitalizations vs placebo in elderly heart failure patients with atrial fibrillation (HR 0.92; 95% CI 0.73-1.17; P=0.46).